[go: up one dir, main page]

HK1133886A1 - Substituted aryl-indole compounds and their kynurenine kynuramine-like metabolites as therapeutic agents - Google Patents

Substituted aryl-indole compounds and their kynurenine kynuramine-like metabolites as therapeutic agents

Info

Publication number
HK1133886A1
HK1133886A1 HK10101675.8A HK10101675A HK1133886A1 HK 1133886 A1 HK1133886 A1 HK 1133886A1 HK 10101675 A HK10101675 A HK 10101675A HK 1133886 A1 HK1133886 A1 HK 1133886A1
Authority
HK
Hong Kong
Prior art keywords
kynuramine
kynurenine
metabolites
substituted aryl
therapeutic agents
Prior art date
Application number
HK10101675.8A
Other languages
Chinese (zh)
Inventor
Tal Peleg-Shulman
Moshe Laudon
Dvorah Daily
Original Assignee
Neurim Pharma 1991
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurim Pharma 1991 filed Critical Neurim Pharma 1991
Publication of HK1133886A1 publication Critical patent/HK1133886A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/10Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16Tryptamines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C225/00Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
    • C07C225/22Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00Carboxylic acid nitriles
    • C07C255/49Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/58Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00Sulfones; Sulfoxides
    • C07C317/26Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C317/32Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C07C317/34Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring
    • C07C317/36Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring with the nitrogen atoms of the amino groups bound to hydrogen atoms or to carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/10Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14Radicals substituted by nitrogen atoms, not forming part of a nitro radical

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
HK10101675.8A 2006-10-03 2010-02-12 Substituted aryl-indole compounds and their kynurenine kynuramine-like metabolites as therapeutic agents HK1133886A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84864206P 2006-10-03 2006-10-03
PCT/IB2007/004306 WO2008041140A2 (en) 2006-10-03 2007-10-03 Substituted aryl-indole compounds and their kynurenine/kynuramine-like metabolites as therapeutic agents

Publications (1)

Publication Number Publication Date
HK1133886A1 true HK1133886A1 (en) 2010-04-09

Family

ID=39271279

Family Applications (1)

Application Number Title Priority Date Filing Date
HK10101675.8A HK1133886A1 (en) 2006-10-03 2010-02-12 Substituted aryl-indole compounds and their kynurenine kynuramine-like metabolites as therapeutic agents

Country Status (14)

Country Link
US (3) US7622495B2 (en)
EP (2) EP2086932B1 (en)
JP (1) JP5426386B2 (en)
CN (1) CN101528689B (en)
AR (1) AR063128A1 (en)
CL (1) CL2007002858A1 (en)
DK (1) DK2086932T3 (en)
ES (1) ES2523026T3 (en)
HK (1) HK1133886A1 (en)
PL (1) PL2086932T3 (en)
PT (1) PT2086932E (en)
SI (1) SI2086932T1 (en)
TW (1) TWI407954B (en)
WO (1) WO2008041140A2 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2091943B1 (en) 2006-10-21 2013-11-20 AbbVie Deutschland GmbH & Co KG Heterocyclic compounds and their use as glycogen synthase kinase 3 inhibitors
CA2726833C (en) 2008-06-06 2016-03-22 Pharma Two B Ltd. Pharmaceutical compositions for treatment of parkinson's disease
EP2621914B1 (en) 2010-09-27 2016-12-28 Abbott GmbH & Co. KG Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
EP2651404B1 (en) 2010-12-14 2015-10-14 Electrophoretics Limited Casein kinase 1delta (ck1delta) inhibitors
US9090592B2 (en) 2010-12-30 2015-07-28 AbbVie Deutschland GmbH & Co. KG Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
US9580398B2 (en) 2012-04-02 2017-02-28 The Trustees Of Columbia University In The City Of New York Compounds, compositions, and methods for modulating ferroptosis and treating excitotoxic disorders
WO2014152752A1 (en) * 2013-03-14 2014-09-25 Vistagen Therapeutics, Inc. Methods for the synthesis of chiral kynurenine compounds
JP6664814B2 (en) * 2014-08-18 2020-03-13 国立大学法人大阪大学 New 2-aminobenzoyl derivatives
AU2015367396C1 (en) * 2014-12-19 2019-05-16 The University Court Of The University Of Edinburgh 3-(6-alkoxy-5-chlorobenzo[d]isoxazol-3-yl)propanoic acid useful as kynurenine monooxygenase inhibitors
JOP20170131B1 (en) * 2016-06-10 2021-08-17 Lilly Co Eli 1-trahydropyranylcarbonyl-2,3-dihydro-1h-indole compounds for treating cancer
CN106362155A (en) * 2016-10-08 2017-02-01 无锡汉强医药科技有限公司 Application of GSK3 inhibitor in preparing medicine for treating Niemann-Pick disease type C
CN106995828B (en) * 2017-02-04 2020-10-09 中国科学院成都生物研究所 Production of N from Camptotheca acuminata suspension cells1Method for preparing (acetyl) kynuramine
JPWO2018216705A1 (en) * 2017-05-23 2020-03-26 国立大学法人京都大学 Agent for preventing and / or treating neurodegenerative diseases
US11712425B2 (en) 2018-03-14 2023-08-01 Albert Einstein College Of Medicine Immunoregulatory role of 3-OH-kynurenamine and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2870162A (en) 1954-04-28 1959-01-20 Upjohn Co Production of certain tryptamines and compounds produced in the process
JPS5336455B2 (en) 1973-02-03 1978-10-03
IL79264A0 (en) 1986-06-27 1986-09-30 Univ Ramot Tryptamine derivatives,pharmaceutical compositions containing them and their use in an assay for melatonin receptors
AUPO274596A0 (en) 1996-10-04 1996-10-31 Armstrong, Stuart Maxwell Method for the treatment of neurological or neuropsychiatric disorders
US6410584B1 (en) * 1998-01-14 2002-06-25 Cell Pathways, Inc. Method for inhibiting neoplastic cells with indole derivatives
JP2000007626A (en) 1998-06-25 2000-01-11 Taisho Pharmaceut Co Ltd N-substituted nitroaniline derivatives
IL138825A (en) 2000-10-03 2006-06-11 Neurim Pharma 1991 Pharmaceutical formulations containing derivatives of tryptamine and analogous compounds, and some such novel compounds
ATE292115T1 (en) * 2001-09-27 2005-04-15 Hoffmann La Roche INDOLE DERIVATIVES AS COX-II INHIBITORS
TWI317634B (en) * 2001-12-13 2009-12-01 Nat Health Research Institutes Aroyl indoles compounds
IL156669A0 (en) 2003-06-26 2004-01-04 Neurim Pharma 1991 2-aminobenzoyl derivatives
US7834016B2 (en) 2004-09-22 2010-11-16 Janssen Pharmaceutica Nv Inhibitors of the interaction between MDM2 and p53

Also Published As

Publication number Publication date
US7622495B2 (en) 2009-11-24
JP5426386B2 (en) 2014-02-26
US20080132559A1 (en) 2008-06-05
DK2086932T3 (en) 2014-11-10
PL2086932T3 (en) 2015-02-27
TWI407954B (en) 2013-09-11
CL2007002858A1 (en) 2008-05-16
EP2086932B1 (en) 2014-08-27
US20110319494A1 (en) 2011-12-29
JP2010505816A (en) 2010-02-25
CN101528689A (en) 2009-09-09
AR063128A1 (en) 2008-12-30
US20100048663A1 (en) 2010-02-25
PT2086932E (en) 2014-11-10
EP2086932A2 (en) 2009-08-12
WO2008041140A2 (en) 2008-04-10
CN101528689B (en) 2013-04-24
SI2086932T1 (en) 2014-12-31
ES2523026T3 (en) 2014-11-20
WO2008041140A8 (en) 2009-07-09
WO2008041140A3 (en) 2008-08-14
US8236858B2 (en) 2012-08-07
EP2664615A1 (en) 2013-11-20
TW200824684A (en) 2008-06-16
US8003702B2 (en) 2011-08-23

Similar Documents

Publication Publication Date Title
PL2086932T3 (en) Substituted aryl-indole compounds and their kynurenine/kynuramine-like metabolites as therapeutic agents
IL249941A0 (en) Spiro-oxindole compounds and their use as therapeutic agents
GB0625659D0 (en) Therapeutic compounds and their use
HK1199874A1 (en) Spiro-oxindole compounds and their uses as therapeutic agents
GB0719803D0 (en) Therapeutic compounds and their use
GB0719644D0 (en) Therapeutic compounds and their use
GB0609492D0 (en) Therapeutic agents
GB0608928D0 (en) Therapeutic agents
IL186615A0 (en) Spiroheterocylic compounds and their uses as therapeutic agents
GB0601962D0 (en) Therapeutic agents
GB0616214D0 (en) Therapeutic Agents
GB0724251D0 (en) Therapeutic compounds and their use
HU0500170D0 (en) New compounds with therapeutic effects
GB0722680D0 (en) Therapeutic compounds and their use
GB0611152D0 (en) Therapeutic agents
GB0620818D0 (en) Therapeutic agents
GB0620059D0 (en) Therapeutic agents
GB0609676D0 (en) Therapeutic agents
EP2231163A4 (en) Compounds and therapeutic use thereof
GB0622195D0 (en) Therapeutic agents
GB0614538D0 (en) Therapeutic Compounds And Their Use
GB0705517D0 (en) Therapeutic compounds and their use
GB0625633D0 (en) Therapeutic compounds and their use
GB0711465D0 (en) Silan-3-amines and disilan-5-amines as therapeutic agents
GB0601818D0 (en) Therapeutic agent

Legal Events

Date Code Title Description
CHRG Changes in the register

Free format text: CORRECTION OF THE NAME OF APPLICANT FROM NEURIM PHARMACEUTICALS (1991) LIMITED TO NEURIM PHARMACEUTICALS (1991) LTD

PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20191003